Your Body Keeps the Score:
Understanding Allostatic Load
*Published by Nomena | Estimated reading time: 8 minutes*
You’ve done everything right.
You’ve invested in your health, your relationships, your work. You’ve read the books, hired the coaches, tracked the metrics. By every external measure, you’re operating well. And yet something is not quite adding up. The clarity you once accessed easily now requires effort. Patience runs thinner than it used to, especially at the moments when it matters most. The feeling of genuine rest and restoration has become harder to come by.
This is not a personal failure. It’s not burnout, nor a signal that you have simply taken on too much. It’s something older, more biological, and far more specific than any of those frameworks suggest.
It’s called allostatic load. And for people who have spent years holding a great deal together, it often goes unnoticed until it can't be ignored anymore.
What Allostatic Load Actually Is
The term was introduced in the early 1990s by neuroscientist Bruce McEwen and psychologist Eliot Stellar to name something stress researchers had been observing but never precisely defined. It's the cumulative wear-and-tear your body accumulates when it's repeatedly pushed to meet the demands of life without ever fully returning to baseline.1 Allostatic load can be measured through composite biomarker panels but these are generally not standard in annual bloodwork.
Your body is built to handle stress. When a challenge presents itself, cortisol and adrenaline rise. Heart rate increases. Attention sharpens. Immune defenses mobilize. The biological response is not a malfunction. It’s one of the most sophisticated regulatory systems in nature.
The problem is not the response. It’s the incomplete recovery.
When faced with short-term stressors, the system activates, responds, and resets. Then cortisol clears and the nervous system settles so that equilibrium can return. But for people navigating sustained, high-stakes complexity across multiple fronts simultaneously (think professional, financial, personal, reputational), that reset never fully arrives. The nervous system remains subtly primed and holds a low-grade tension it cannot discharge. And over years, that accumulated unbalancing becomes allostatic load. It’s not a single stressor, but the compounded residue of all of them.
What the Research Shows About Its Consequences
McEwen's subsequent decades of research at Rockefeller University established that high allostatic load is not simply a state of feeling stressed.2 It produces measurable, structural changes across multiple biological systems.
What It Does to the Brain
Chronically elevated cortisol selectively degrades the prefrontal cortex, the region governing executive function, strategic judgment, impulse regulation, and cognitive flexibility. Simultaneously, it enlarges the amygdala, the brain's threat-detection centre.3 The result, gradually and invisibly, is a nervous system increasingly biased toward reactivity rather than presence. For many, threat-scanning becomes the new normal. But because this shift happens so gradually, it's nearly impossible to reverse through willpower alone.
What It Does to Sleep
Sleep disruption is both a symptom and a perpetuator of allostatic load. A nervous system in chronic low-grade vigilance doesn’t fully deactivate at night. The result is sleep that looks adequate on a tracker but lacks the core restorative functions of sufficient slow-wave sleep, proper memory consolidation, and the hormonal repair cycles.4 People carrying significant allostatic load commonly report that they sleep but never feel rested. More hours won’t resolve this since the problem isn’t duration.
What It Does to Biological Aging
The research connecting high allostatic load to accelerated biological aging is substantial. Studies have linked elevated allostatic load scores to shorter telomere length, increased inflammatory markers, immune dysregulation, and heightened risk of cardiovascular and metabolic disease.5 This indicates that your body is aging at a faster rate than its chronological years would suggest.
Why Standard Interventions Have a Ceiling
The wellness industry has built an entire infrastructure around allostatic load without naming it. Sleep optimization, heart rate variability training, cold exposure, breathwork, adaptogens, coaching, integrative medicine all address real variables. Many of them work, but only to a point.
The limit is that they operate at the level of the symptom rather than the underlying architecture.
Long-term stress adaptation doesn’t only change how your body feels. It changes your brain's synaptic structure, its receptor sensitivity, and the expression of key neurotrophic proteins, which are the growth factors responsible for neuronal repair and regeneration. Specifically, chronic stress suppresses brain-derived neurotrophic factor (BDNF), which is essential for synaptic plasticity and neuronal health, and dysregulates the dopaminergic circuits involved in motivation, reward, and genuine recovery.6 This degraded foundation requires an intervention that works at the level of the foundation.
Where Ibogaine Enters the Conversation
Ibogaine is an indole alkaloid derived from the root bark of Tabernanthe iboga, a shrub native to equatorial West Africa, where it's been used in healing traditions for generations. In contemporary clinical settings, it's understood as a multi-receptor neurological agent with a pharmacological profile unlike anything in conventional medicine.
A Multi-System Recalibration
Ibogaine simultaneously engages NMDA receptors (involved in pain processing, memory, and neuroplasticity), serotonin and dopamine transporters, and nicotinic acetylcholine receptors.7 This multi-system engagement produces a coordinated recalibration across the neurotransmitter systems that chronic stress has progressively degraded. No single-target pharmaceutical can replicate this.
Critically, ibogaine upregulates the production of BDNF and GDNF (glial cell line-derived neurotrophic factor), which are precisely the growth factors that allostatic load suppresses.8 Research published in Frontiers in Pharmacology in 2019 by Marton and colleagues demonstrated that ibogaine administration significantly increased BDNF and GDNF expression in the brain regions most central to motivation, emotional regulation, and the dopaminergic pathways that allostatic load most directly degrades.9
GDNF is one of the most potent regeneration factors for dopaminergic neurons, which are the neurons that govern motivation, presence, and reward processing.
What the Clinical Evidence Shows
The most rigorous peer-reviewed study of ibogaine to date was published in Nature Medicine in January 2024 in conjunction with Stanford University.10 This observational study examined 30 Special Operations veterans with significant allostatic burden from repeated trauma exposure using an ibogaine flood dose protocol. Results showed significant improvements in overall functioning, depression, anxiety, and post-traumatic stress severity.
To put this in context, overall functioning improved by nearly 3x what's considered clinically significant. But these results aren’t isolated in the ibogaine literature. They’re consistent with a compound that acts at the level of neurobiology rather than managing its surface expressions.
The Window That Opens Afterward
What makes ibogaine categorically different isn't just what happens during the 24-to-36-hour experience. It's what happens in the weeks after.
Research published in Nature in 2023 by Nardou and colleagues at Johns Hopkins established that ibogaine reopens a "critical period" of heightened neuroplasticity in the adult brain.11 This is the same state of accelerated neural flexibility that characterizes early childhood development, when the brain learns most rapidly and is most responsive to new information and experience. In adulthood, this window is ordinarily closed. Ibogaine reopens it, creating what can be described as a "second neurological childhood" where the brain regains its early capacity for learning and adaptation.
What follows is a period of 72 hours or more when your brain becomes measurably more receptive to forming new patterns, releasing entrenched ones, and consolidating intentional change.
This window is a biological opportunity that, when met with structured integration and appropriate therapeutic support, can translate a neurological reset into enduring change in behavior, relationship, and mental presence.
Why Integration Is Part of the Protocol, Not an Afterthought
At Nomena, the post-ibogaine window is treated as a distinct clinical phase. The neuroplasticity that ibogaine initiates doesn't last indefinitely, but the personal changes you build during this window can. During this period, new habits encode most efficiently, old patterns are most open to change, and the nervous system is most capable of reorganizing around intentional inputs rather than reflexive defaults.
Specific, personalized, and structured integration, designed around each client's goals, is where the return on this investment is actually realized. At Nomena, this is not aftercare. It’s the second half of the protocol.
What This Means If You Recognize Yourself Here
If any part of this article has described something you've been living with, the relevant question isn't whether something needs attention. It's what that something actually is, and what level of intervention it requires.
Allostatic load isn't a performance problem you can hack with productivity gadgets. It's a biological condition. Understanding that distinction clearly is the first step toward addressing it at the depth it demands.
**[Request a confidential clinical assessment with Nomena](#)**
References
1: McEwen, B.S., & Stellar, E. (1993). Stress and the individual: Mechanisms leading to disease. Archives of Internal Medicine, 153(18), 2093--2101. https://doi.org/10.1001/archinte.1993.00410180039004
2: McEwen, B.S. (1998). Stress, adaptation, and disease: Allostasis and allostatic load. Annals of the New York Academy of Sciences, 840, 33--44. https://doi.org/10.1111/j.1749-6632.1998.tb09546.x
3: Arnsten, A.F.T. (2009). Stress signalling pathways that impair prefrontal cortex structure and function. Nature Reviews Neuroscience, 10(6), 410--422. https://doi.org/10.1038/nrn2648
4: McEwen, B.S., & Karatsoreos, I.N. (2015). Sleep deprivation and circadian disruption: Stress, allostasis, and allostatic load. Sleep Medicine Clinics, 10(1), 1--10. https://doi.org/10.1016/j.jsmc.2014.11.007
5: Seeman, T.E., McEwen, B.S., Rowe, J.W., & Singer, B.H. (2001). Allostatic load as a marker of cumulative biological risk: MacArthur Studies of Successful Aging. Proceedings of the National Academy of Sciences, 98(8), 4770--4775. https://doi.org/10.1073/pnas.081072698
6: Duman, R.S., & Monteggia, L.M. (2006). A neurotrophic model for stress-related mood disorders. Biological Psychiatry, 59(12), 1116--1127. https://doi.org/10.1016/j.biopsych.2006.02.013
7: Bulling, S., Schicker, K., Zhang, Y.W., et al. (2012). The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. Journal of Biological Chemistry, 287(22), 18524--18534. https://doi.org/10.1074/jbc.M112.343681
8: Marton, S., Gonzalez, B., Rodriguez-Bottero, S., et al. (2019). Ibogaine administration modifies GDNF and BDNF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits. Frontiers in Pharmacology, 10, 193. https://doi.org/10.3389/fphar.2019.00193
9: Ibid.
10: Cherian, K.N., Keynan, J.N., Anker, L., et al. (2024). Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine, 30, 373--381. https://doi.org/10.1038/s41591-023-02705-w
11: Nardou, R., Sawyer, E., Song, Y.J., et al. (2023). Psychedelics reopen the social reward learning critical period. Nature, 618, 790--798. https://doi.org/10.1038/s41586-023-06204-3